Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Artrya Limited ( (AU:AYA) ).
Artrya Limited announced significant developments at its 2025 Annual General Meeting, highlighting FDA clearance for its Salix Coronary Anatomy and Plaque modules, and progress on the Coronary Flow module. The company is transitioning from research and development to a commercial phase, focusing on the U.S. market due to its size and growth potential. Artrya is establishing a base in Atlanta, Georgia, to support its U.S. operations and has raised $80 million to fund its path to profitability. The company’s unique point-of-care capability and lack of market penetration by competitors position it well for growth.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company that focuses on developing AI-powered solutions for the detection and management of coronary artery disease. The company’s proprietary software analyzes coronary CT scans to identify key biomarkers of heart disease, aiding clinicians in more accurate and efficient diagnoses. Artrya is engaged in regulatory and commercial activities across key international markets to advance cardiac care through innovative technology.
Average Trading Volume: 965,503
Technical Sentiment Signal: Buy
Current Market Cap: A$580.2M
Find detailed analytics on AYA stock on TipRanks’ Stock Analysis page.